ADCTNYSEPharmaceutical PreparationsFiscal year ends December 31
ADC Therapeutics SA
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.44+0.04 (+2.86%)
Close on Oct 19, 2026
- Market cap
- $223.22M
- P/E (TTM)
- –
- Dividend yield
- –
ADC Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | ADC Therapeutics | Industry median |
|---|---|---|
| Market Cap | $183.84M | $197.05M |
| Enterprise Value | -$29.09M | $106.56M |
| PS Ratio | 2.31 | 3.93 |
Enterprise value
| Measure | ADC Therapeutics | Industry median |
|---|---|---|
| EV / Sales | -0.37 | 2.69 |
Income (trailing twelve months)
| Measure | ADC Therapeutics | Industry median |
|---|---|---|
| Revenue | $79.58M | $57.94M |
| Operating Income | -$99.55M | -$21.44M |
| Pretax Income | -$97.31M | -$14.45M |
| Net Income | -$96.91M | -$22.46M |
| EBITDA | -$99.55M | -$16.91M |
| EPS (Diluted) | -$0.66 | -$0.83 |
Margins
| Measure | ADC Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -125.1% | -44.5% |
| Pretax Margin | -122.3% | -13.0% |
| Profit Margin | -121.8% | -39.2% |
| EBITDA Margin | -125.1% | -31.3% |
| FCF Margin | -128.5% | -8.85% |
Returns
| Measure | ADC Therapeutics | Industry median |
|---|---|---|
| Return on Assets (ROA) | -32.3% | -41.0% |
| Return on Capital Employed (ROCE) | -51.6% | -37.8% |
Growth
| Measure | ADC Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 3.03% | 6.01% |
| Revenue Growth (3Y CAGR) | -27.1% | 2.25% |
Balance sheet
| Measure | ADC Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $219.11M | $62.42M |
| Total Debt | $6.18M | $120.13M |
| Net Cash (Debt) | $212.93M | $15.68M |
| Net Cash Per Share | $1.67 | $0.65 |
| Equity (Book Value) | -$228.21M | $48.79M |
| Book Value Per Share | -$1.79 | $1.36 |
| Tangible Book Value | -$228.21M | $23.06M |
| Working Capital | $175.38M | $75.77M |
Financial position
| Measure | ADC Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 3.03 | 3.30 |
| Quick Ratio | 2.54 | 2.39 |
| Interest Coverage | -1.90 | -7.12 |
Cash flow (trailing twelve months)
| Measure | ADC Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$102.27M | -$12.35M |
| Capital Expenditures | -$32.00K | -$1.06M |
| Free Cash Flow | -$102.30M | -$20.28M |
| FCF Per Share | -$0.80 | -$0.41 |
Efficiency
| Measure | ADC Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.26 | 0.38 |
| Revenue Per Employee | $423.32K | $398.96K |
| Profits Per Employee | -$515.47K | -$732.08K |
| Employee Count | 188 | 73 |
Dividends and yields
| Measure | ADC Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -52.7% | -21.2% |
| FCF Yield | -55.6% | -7.64% |
| Buyback Yield | -23.4% | -0.58% |
| Shareholder Yield | -23.4% | 0.00% |
Shares
| Measure | ADC Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 127,668,000 | 59,128,900 |
| Shares Change (YoY) | 38.2% | 11.1% |
| Shares Change (QoQ) | 0.21% | 0.54% |
| Float | 73,011,900 | 48,744,500 |
| Shares Held by Insiders | 42.8% | 11.8% |
Taxes
| Measure | ADC Therapeutics | Industry median |
|---|---|---|
| Income Tax | -$404.00K | $91.50K |
Scores
| Measure | ADC Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -8.37 | 0.10 |
| Piotroski F-Score | 6 | 4 |
Calculated by StockData from ADC Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.